Study to Evaluate the Effect of Food Intake on the Plasma Concentration Changes of Quetiapine After Oral Administration of FK949E in Healthy Volunteers

NCT ID: NCT01871987

Last Updated: 2017-03-09

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 24 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2009-06-30
• Study Completion Date: 2009-08-31

Brief Summary

A study to evaluate the effect of food on the plasma concentration changes of quetiapine after oral administration of FK949E (extended release formulation of quetiapine) in healthy male subjects.

Detailed Description

This is a 3-way cross-over study.

Conditions

Healthy; Plasma Concentration Change of Quetiapine

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: OTHER
• Blinding Strategy: NONE

Study Groups

fasted group

receiving FK949E in fasted condition

Group Type: EXPERIMENTAL

FK949E

Intervention Type: DRUG

oral

low fat group

receiving FK949E after low fat meal

Group Type: EXPERIMENTAL

FK949E

Intervention Type: DRUG

oral

high fat group

receiving FK949E after high fat meal

Group Type: EXPERIMENTAL

FK949E

Intervention Type: DRUG

oral

Interventions

FK949E

oral

Intervention Type: DRUG

Other Intervention Names

extended release formulation of quetiapine

Eligibility Criteria

Inclusion Criteria

• Body weight : ≥50.0 kg, <85.0 kg
• Body Mass Index : ≥17.6, <26.4
• Healthy, as judged by the investigator/subinvestigator based on the results of physical examinations (subjective symptoms and objective findings) and all tests obtained at screening and during the period from hospital admission in Period 1 to immediately before study medication

Exclusion Criteria

• Subjects with the following history.

1. Hepatic disease (e.g. viral hepatitis, drug-induced liver injury).

2. Heart disease (e.g. congestive heart failure, angina pectoris, arrhythmia requiring

treatment).

3. Respiratory disease (e.g. serious bronchial asthma, chronic bronchitis)

4. Gastrointestinal disease (e.g. serious peptic ulcer, gastroesophageal reflux esophagitis;

diseases requiring several selections except for appendicitis)

5. Renal disease (e.g. acute renal failure, glomerulonephritis, interstitial nephritis).

6. Cerebrovascular disorder (e.g. cerebral infarction).

7. Malignant tumor.

8. Drug allergies. Allergic disorders (except for hay fever)

9. Any use of drugs abuse. Alcohol abuse

• Any concurrent illness (except for caries)
• A deviation from the normal reference range of blood pressure, pulse rate, body temperature, or 12-lead ECG at screening or upon admission in Period 1 (day preceding the day of study medication).
• Any deviation of the following criteria for clinical laboratory tests at screening or upon admission in Period 1 (day preceding the day of study medication). The normal reference ranges specified at the study site will be used as the normal reference ranges in the present study.

1. Hematology:

• A deviation of ±20% from the upper or lower limit of the normal range

2. Blood biochemistry:

• A deviation from the normal range for AST, ALT, creatinine (Cre), or serum electrolytes.
• A deviation of ±20% from the upper or lower limit of the normal range for other items than the above.
• However, the lower limit of the normal range will not be established for items for which a deviation from the lower limit is not considered clinically significant[AST, ALT, total bilirubin (T-Bil), ALP, γ-GTP, LDH, CK, Cre, uric acid (UA)and total cholesterol (T-Cho)].

3. Urinalysis:

• U-Glu, U-Pro ≥+1
• U-Uro ≥+2

4. Urinary drug test: A positive result for phencyclidine, benzodiazepine, cocaine, amphetamines, cannabis, opiates, barbiturates or tricyclic antidepressants

5. Immunological test: A positive result for HBs antigen, HCV antibody, syphilis, or HIV antigen/antibody

• Received medication within 14 days before hospital admission in Period 1 or is scheduled to receive medication
• Received any investigational drugs in other clinical or post-marketing studies within 120 days before the screening assessment
• Previous treatment with FK949E
• Donated more than 400 mL of whole blood within 90 days, more than 200 mL of whole blood within 30 days, or blood components within 14 days before the screening assessment
• Excessive smoking or drinking habit (measure of "excessive": alcohol: 45 g/day [a 633 mL bottle of beer contains 25 g of alcohol, and 180 mL of Japanese sake contains 22 g of alcohol], smoking: 20 cigarettes/day).
• Other subjects concerned ineligible by the investigator/subinvestigator

• Minimum Eligible Age: 20 Years
• Maximum Eligible Age: 44 Years
• Eligible Sex: MALE
• Accepts Healthy Volunteers: Yes

Sponsors

Astellas Pharma Inc

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Medical Director

Role: STUDY_DIRECTOR

Astellas Pharma Inc

Locations

Kyushu, , Japan

Countries

Japan

Related Links

https://www.astellasclinicalstudyresults.com/hcp/study.aspx?ID=178

Link to results on Astellas Clinical Study Results website

Other Identifiers

6949-CL-0003

Identifier Type: -

Identifier Source: org_study_id